The recent decision by the U.S. Court of Appeals for the Federal Circuit in Restem v. Jadi Cell confirmed that product-by-process claims are considered novel if the product itself is new, regardless of whether the process steps were described in the prior art.

In a landmark decision dated March 20, 2026, the Unified Patent Court (UPC) allowed a change in the language of proceedings in the case of HyGear v. Topsoe from German to English. The decision by Florence Butin, President of the UPC Court of First Instance, clarifies the balance between the principle of fairness, the interests of defendants, and the specifics of expedited procedures, setting an important precedent for transnational patent disputes before the UPC.

Klondike Agricultural Products has achieved a true breakthrough in agriculture by securing two key U.S. patents for a "smart" seed capsule and the high-speed robotic engine required for its production—a feat that could permanently eliminate the problem of crop failure for farmers.

In the realm of intellectual property, few disputes impact science, business, and medicine as profoundly as the years-long battle over patents for CRISPR technology ("genetic scissors"). In March 2026, this conflict took a new turn: Nobel laureates Jennifer Doudna and Emmanuelle Charpentier once again lost a pivotal ruling in the United States.

Every year on January 1st, a quiet yet culturally monumental event takes place in the U.S.: new works enter the public domain, meaning they become free for anyone to use. In 2026, this wave has swept up a whole range of iconic characters, books, and cartoons originally created in the 1930s.

А recent decision by a federal court in Delaware demonstrates that the limits of this protection in the modern procurement environment are not unlimited. The case concerned a patent dispute surrounding Moderna’s COVID-19 vaccine. At its core was the interpretation of the phrase “for the Government” in Section 1498 and its application to products developed under government contracts.